175 related articles for article (PubMed ID: 26634205)
1. Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
Wu H; Liu Y; Kang H; Xiao Q; Yao W; Zhao H; Wang E; Wei M
Biomed Res Int; 2015; 2015():279109. PubMed ID: 26634205
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
[TBL] [Abstract][Full Text] [Related]
3. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Cui L; Huang J; Zhan Y; Qiu N; Jin H; Li J; Huang H; Li H
Life Sci; 2021 Jul; 276():119392. PubMed ID: 33774021
[TBL] [Abstract][Full Text] [Related]
4. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
[TBL] [Abstract][Full Text] [Related]
5. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
6. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
7. Association between the ABCG2 C421A polymorphism and Alzheimer's disease.
Fehér Á; Juhász A; László A; Pákáski M; Kálmán J; Janka Z
Neurosci Lett; 2013 Aug; 550():51-4. PubMed ID: 23827224
[TBL] [Abstract][Full Text] [Related]
8. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Müller PJ; Dally H; Klappenecker CN; Edler L; Jäger B; Gerst M; Spiegelhalder B; Tuengerthal S; Fischer JR; Drings P; Bartsch H; Risch A
Int J Cancer; 2009 Apr; 124(7):1669-74. PubMed ID: 19107936
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
[TBL] [Abstract][Full Text] [Related]
12. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
13. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
16. Associations between ABCG2 gene polymorphisms and isolated septal defects in a Han Chinese population.
Wang C; Xie L; Li H; Li Y; Mu D; Zhou R; Liu R; Zhou K; Hua Y
DNA Cell Biol; 2014 Oct; 33(10):689-98. PubMed ID: 24979295
[TBL] [Abstract][Full Text] [Related]
17. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
18. The ABCG2 gene Q141K polymorphism contributes to an increased risk of gout: a meta-analysis of 2185 cases.
Qiu Y; Liu H; Qing Y; Yang M; Tan X; Zhao M; Lin M; Zhou J
Mod Rheumatol; 2014 Sep; 24(5):829-34. PubMed ID: 24499401
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia.
Wang F; Liang YJ; Wu XP; Chen LM; To KK; Dai CL; Yan YY; Wang YS; Tong XZ; Fu LW
Eur J Cancer; 2011 Sep; 47(13):1990-9. PubMed ID: 21531129
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
